Keisuke Hirai, PhD, Osaka University

Affiliations: 
Takeda Chemical Industries 
Area:
Neurodegenerative diseases
Google:
"Keisuke Hirai"
Bio:

http://www.tpna.com/newsroom/press_release_detail.aspx?year=2003&articleid=88

Mean distance: 16.9 (cluster 28)
 
SNBCP
Cross-listing: Neurotree - Neuropathology Tree

Parents

Sign in to add mentor
George Perry post-doc 1997-1998 Case Western
Mark Anthony Smith post-doc 1997-1998 Case Western (Neurotree)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Nishiyama K, Hirai K. (2015) In vitro comparison of duration of action of melatonin agonists on melatonin MT1 receptor: possible link between duration of action and dissociation rate from receptor. European Journal of Pharmacology. 757: 42-52
Nishiyama K, Hirai K. (2014) The melatonin agonist ramelteon induces duration-dependent clock gene expression through cAMP signaling in pancreatic INS-1 β-cells. Plos One. 9: e102073
Nishiyama K, Nishikawa H, Kato K, et al. (2014) Pharmacological characterization of M-II, the major human metabolite of ramelteon. Pharmacology. 93: 197-201
Fujimoto T, Kunitomo J, Tomata Y, et al. (2011) Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 21: 6414-6
Koike T, Takai T, Hoashi Y, et al. (2011) Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands. Journal of Medicinal Chemistry. 54: 4207-18
Koike T, Hoashi Y, Takai T, et al. (2011) 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MTâ‚‚-selective agonists. Journal of Medicinal Chemistry. 54: 3436-44
Hirai K, Kato K, Nishikawa H, et al. (2010) [Preclinical pharmacological profiles and clinical outcome of the novel melatonin-receptor agonist ramelteon (Rozerem 8 mg).]. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 136: 51-60
Nishiyama K, Shintani Y, Hirai K, et al. (2009) Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon. The Journal of Pharmacology and Experimental Therapeutics. 330: 855-63
Nunomura A, Honda K, Takeda A, et al. (2006) Oxidative damage to RNA in neurodegenerative diseases. Journal of Biomedicine & Biotechnology. 2006: 82323
Zhu X, Perry G, Moreira PI, et al. (2006) Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. Journal of Alzheimer's Disease : Jad. 9: 147-53
See more...